About Grunenthal
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.
Key Details
Profiles
Please note, this profile is not managed by Grunenthal. The information on this profile may have been submitted by an independent community member or obtained from a public source. As a result, it may be outdated or inaccurate. Logo provided by Clearbit to help identify the profile for review purposes. Cademy is an unbiased information source and does not have any affiliation with or directly endorse this profile.
Primary Location
- Tor Building, Saint-Cloud Way
- Maidenhead
- United Kingdom
- SL6 8BN
All Locations
- Tor Building, Saint-Cloud Way, Maidenhead